-
Product Insights
NewUrinary Tract Infections – Drugs In Development, 2024
Empower your strategies with our Urinary Tract Infections – Drugs In Development, 2024 report and make more profitable business decisions. A urinary tract infection (UTI) is a bacterial infection that can occur in any part of the urinary system, including the kidneys, bladder, ureters, and urethra. Common symptoms include pain or burning during urination, frequent urination, urgency, lower abdominal discomfort, and cloudy or foul-smelling urine. UTIs are more common in women, and risk factors include factors such as sexual activity, urinary...
-
Product Insights
NewHospital Acquired Pneumonia (HAP) – Drugs In Development, 2024
Empower your strategies with our Hospital Acquired Pneumonia (HAP) – Drugs In Development, 2024 report and make more profitable business decisions. Hospital-acquired pneumonia (HAP) is defined as pneumonia acquired during a hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache, and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis, and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle. The Hospital Acquired Pneumonia (HAP) drugs in development market research report...
-
Product Insights
NewVentilator Associated Pneumonia (VAP) – Drugs In Development, 2024
Empower your strategies with our Ventilator Associated Pneumonia (VAP) – Drugs In Development, 2024 report and make more profitable business decisions. Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia (VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing amounts of oxygen in...
-
Product Insights
NewMycoses – Drugs In Development, 2024
Empower your strategies with our Mycoses – Drugs In Development, 2024 report and make more profitable business decisions. Mycoses, also known as fungal infections, encompass a diverse group of diseases caused by fungi. These infections can affect various tissues in the body, including the skin, nails, and internal organs. Superficial mycoses, like athlete's foot and ringworm, involve the outer layers, while systemic mycoses can affect deeper tissues and may be more severe, particularly in individuals with weakened immune systems. Candidiasis is...
-
Product Insights
NewAcinetobacter Infections – Drugs In Development, 2024
Empower your strategies with our Acinetobacter Infections – Drugs In Development, 2024 report and make more profitable business decisions. Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, or urinary tract). Symptoms include fever and red, swollen, warm, or painful skin areas or wounds. Predisposing factors include weak immune system, poor hygiene, and recent surgery or procedure. The Acinetobacter Infections drugs in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OMN-6 in Hospital Acquired Pneumonia (HAP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OMN-6 in Hospital Acquired Pneumonia (HAP) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OMN-6 in Hospital Acquired Pneumonia (HAP) Drug Details: OMN-6 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OMN-6 in Urinary Tract Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OMN-6 in Urinary Tract Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OMN-6 in Urinary Tract Infections Drug Details: OMN-6 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OMN-6 in Acinetobacter Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OMN-6 in Acinetobacter Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OMN-6 in Acinetobacter Infections Drug Details: OMN-6 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OMN-6 in Ventilator Associated Pneumonia (VAP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OMN-6 in Ventilator Associated Pneumonia (VAP) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OMN-6 in Ventilator Associated Pneumonia (VAP) Drug Details: OMN-6 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tiprelestat in Inflammation
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tiprelestat in Inflammation Drug Details: Tiprelestat (Elafin) is under development for the treatment of inflammatory...